Clinical Cancer Research 10, -, , . doi:
© 2008 American Association for Cancer Research
(Click the button above to download this figure into PowerPoint for use in presentations. Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Note: Users are permitted to download figures from AACR journals into
PowerPoint for use in educational presentations, provided that the citation
and copyright information are displayed on the slide. Commercial use of
these images or reproduction of the images in any other form requires
written permission from the AACR. For more information on permission
requests, send an e-mail message to permissions{at}aacr.org.
Click on image to view larger version.
Fig. 1. A, ELISA showing titration of RM1 antiserum against purified CD55. ELISA plates were coated with 5 µg/ml purified CD55 overnight at 4°C. Protein was detected with mouse antiserum and detected with rabbit antimouse horseradish peroxidase conjugate and absorbance measured at 405 nm. B, Western Blot analysis of decay accelerating factor fusion protein (SCR 1-4Fc) with RM1 monoclonal antibody. Fifty µg/ml SCR 1-4Fc were loaded onto 8% SDS-PAGE gels under nonreducing conditions and transferred to a nitrocellulose matrix. Blots were detected with anti-decay accelerating factor antibodies at a concentration of 2 µg/ml, horseradish peroxidase conjugated antimouse, and developed with ECL reagents. C, immunohistochemical staining of serial breast sections stained with RM1 with and without preincubation with RM1 peptide (original magnification, x400). Specific peptide was used (at 5, 2, 1, and 0.5 µg/ml) to block CD55 to determine any nonspecific binding, and no staining was observed, indicating that the monoclonal antibody anti-SCR3 was specific for the regions to which it was produced.
